The 36-month beta value for REVB is at 0.10. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for REVB is 0.90M, and currently, shorts hold a 6.86% of that float. The average trading volume for REVB on March 17, 2025 was 219.42K shares.
REVB) stock’s latest price update
The stock of Revelation Biosciences Inc (NASDAQ: REVB) has decreased by -25.89 when compared to last closing price of 3.40.Despite this, the company has seen a loss of -25.01% in its stock price over the last five trading days. businesswire.com reported 2025-03-17 that SAN DIEGO–(BUSINESS WIRE)—- $REVB #AKI–Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced Gemini priming attenuates the inflammatory response in human peripheral blood mononuclear cells (PBMCs) exposed to clinically relevant promoter molecules of inflammation. Revelation anticipates demonstrating the same protective effect in patients treated with Gemini in its Phase 1.
REVB’s Market Performance
REVB’s stock has fallen by -25.01% in the past week, with a monthly drop of -39.43% and a quarterly drop of -62.50%. The volatility ratio for the week is 6.79% while the volatility levels for the last 30 days are 9.16% for Revelation Biosciences Inc The simple moving average for the last 20 days is -30.81% for REVB’s stock, with a simple moving average of -83.12% for the last 200 days.
REVB Trading at -49.71% from the 50-Day Moving Average
After a stumble in the market that brought REVB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.86% of loss for the given period.
Volatility was left at 9.16%, however, over the last 30 days, the volatility rate increased by 6.79%, as shares sank -42.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -66.78% lower at present.
During the last 5 trading sessions, REVB fell by -27.08%, which changed the moving average for the period of 200-days by -91.15% in comparison to the 20-day moving average, which settled at $3.64. In addition, Revelation Biosciences Inc saw -65.84% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for REVB
Current profitability levels for the company are sitting at:
- -295768.77 for the present operating margin
The net margin for Revelation Biosciences Inc stands at -557726.45. The total capital return value is set at -1.2. Equity return is now at value -264.85, with -159.69 for asset returns.
Currently, EBITDA for the company is -7.98 billion with net debt to EBITDA at 0.82. When we switch over and look at the enterprise to sales, we see a ratio of -190.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.43.
Conclusion
In conclusion, Revelation Biosciences Inc (REVB) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
